• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research

Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis.
CONCLUSION: The analysis of the French pharmacovigilance database cases allows to confirm an expected and monitored risk profile in the risk management plan for both drugs. Several signals have arisen, some of which will be investigated through a pharmacoepidemiology study. PMID: 33376005 [PubMed - as supplied by publisher]
Source: Therapie - December 13, 2020 Category: Psychiatry & Psychology Authors: Scailteux LM, Lacroix C, Bergeron S, Despas F, Sassier M, Triquet L, Picard S, Oger E, Polard E, et le réseau français des Centres régionaux de pharmacovigilance Tags: Therapie Source Type: research

Clinical research linking Traditional Chinese Medicine constitution types with diseases: a literature review of 1639 observational studies.
CONCLUSION: Eight biased TCM constitutions were closely related to specific diseases, and could be used to guide individualized prevention and treatment. More rigorously designed studies are recommended to further verify the constitution-disease relationship. PMID: 32744037 [PubMed - in process]
Source: Journal of Traditional Chinese Medicine - July 31, 2020 Category: Complementary Medicine Authors: Liang X, Wang Q, Jiang Z, Li Z, Zhang M, Yang P, Wang X, Wang Y, Qin Y, Li T, Zhang T, Wang Y, Sun J, Li Y, Luo H, Li L Tags: J Tradit Chin Med Source Type: research

Neurological Involvement in Primary Systemic Vasculitis
Conclusion Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases. TABLE 1 Table 1. Common CNS and PNS involvements of primary systemic vasculitis. Author Contributions SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients
Conclusion In patients with compensated HCV-related cirrhosis, Asian ethnic origin, arterial hypertension, smoking and low serum albumin are independent predictive factors of cardiovascular events, while a sustained virological response is associated with a decreased rate of cardiovascular events.
Source: American Heart Journal - November 9, 2017 Category: Cardiology Source Type: research

Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France
ConclusionExtrahepatic manifestations of HCV infection substantially add to the overall economic burden of the disease in France. HCV cure after anti‐viral therapy is expected to significantly reduce the total costs of managing these manifestations in France.
Source: Alimentary Pharmacology and Therapeutics - October 18, 2017 Category: Drugs & Pharmacology Authors: P. Cacoub, M. Vautier, A. C. Desbois, D. Saadoun, Z. Younossi Tags: ORIGINAL ARTICLE Source Type: research